Quantifying antibody kinetics and rna detection during early-phase SARS-CoV-2 infection by time since symptom onset

52Citations
Citations of this article
117Readers
Mendeley users who have this article in their library.

Abstract

Understanding and mitigating SARS-CoV-2 transmission hinges on antibody and viral RNA data that inform exposure and shedding, but extensive variation in assays, study group demographics and laboratory protocols across published studies confounds inference of true biological patterns. Our meta-analysis leverages 3214 datapoints from 516 individuals in 21 studies to reveal that seroconversion of both IgG and IgM occurs around 12 days post-symptom onset (range 1–40), with extensive individual variation that is not significantly associated with disease severity. IgG and IgM detection probabilities increase from roughly 10% at symptom onset to 98– 100% by day 22, after which IgM wanes while IgG remains reliably detectable. RNA detection probability decreases from roughly 90% to zero by day 30, and is highest in feces and lower respiratory tract samples. Our findings provide a coherent evidence base for interpreting clinical diagnostics, and for the mathematical models and serological surveys that underpin public health policies.

Cite

CITATION STYLE

APA

Borremans, B., Gamble, A., Prager, K. C., Helman, S. K., McClain, A. M., Cox, C., … Lloyd-Smith, J. O. (2020). Quantifying antibody kinetics and rna detection during early-phase SARS-CoV-2 infection by time since symptom onset. ELife, 9, 1–27. https://doi.org/10.7554/ELIFE.60122

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free